Navigation Links
AACR and Kure It announce 2 Kidney Cancer Research grant recipients
Date:12/21/2012

PHILADELPHIA The American Association for Cancer Research and Kure It are pleased to announce that William Y. Kim, M.D., and James W. Mier, M.D., will each receive a 2012 AACR-Kure It Grant for Kidney Cancer Research.

Kim, assistant professor in the departments of medicine and genetics at the University of North Carolina School of Medicine, in Chapel Hill, and Mier, associate professor at Harvard Medical School in the division of hematology and oncology at Beth Israel Deaconess Medical Center, in Boston, Mass., will each receive $250,000 during the two-year grant term. In addition, Kim and Mier will receive complementary registration to the AACR Annual Meeting 2013, to be held April 6-10 in Washington, D.C., and will be recognized at the Annual Grants Reception and Dinner on Tuesday, April 9.

These grants are designed to provide support for innovative translational kidney cancer research designed to improve the survival and quality of life of patients with kidney cancer and, in turn, lead to individualized therapeutic options for the treatment or development of promising new kidney cancer therapies.

Kim's project, "Defining the RCC [Renal Cell Carcinoma] Kinome for Target Discovery and Individualized Therapy," aims to personalize kinase therapy based on the patient's kidney tumor.

"Despite the fact that kidney cancer has very few activating mutations in kinases, they can be activated through alternate means and remain tenable therapeutic targets in renal cell carcinoma. We will use a novel, quantitative mass spectroscopy-based assay developed at University of North Carolina to assess the global activation state of the kinome and identify both novel as well as currently actionable targets," said Kim, a faculty member of UNC Lineberger Comprehensive Cancer Center.

Mier's research will explore the mechanism by which HDM2 antagonists and vascular endothelial growth factor-targeted drugs act together to block tumor angiogenesis and induce disease regression in renal cell carcinomas in his project, "HDM2/HDMX as a Therapeutic Target in Renal Cell Carcinoma." His work will support the ongoing translational kidney cancer research at Dana-Farber/Harvard Cancer Center.

"I am honored to have been selected for this grant and am grateful to Kure It and the AACR for making the funds available. Everyone in my lab feels encouraged by this award. We are planning to use the funds to carry out preclinical studies of novel agents that may prove useful in patients with RCC. The AACR-Kure It funds will allow us to carry out studies that we might otherwise not have been able to undertake," said Mier.

The expert scientific review committee, assembled by the AACR, received 44 high-caliber applications from independent investigators who proposed to develop and study new ideas and approaches that will have a direct application and relevance to patients with kidney cancer.

The AACR and Kure It are committed to collaboratively sustain the grant to award funding to the most promising kidney cancer research project.


'/>"/>
Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. The JAMA Network announces new names, new embargo schedules for specialty journals
2. Brain Spade Announces Site Launch is Now Set for January – New Year’s Resolutions Now Include Brain Health and Fitness
3. BrainTrain Announces Partnership with Elizabeth Shatner’s All Glory Project
4. HistoWiki.com's Clint Evans Announces Kindle Book Giveaway Which Shows the Missing Links from Michelle Obama's "Let's Move" Weight Loss Program
5. TherapySites (Websites for Therapists) Announces Partnership with Advanced Data Systems
6. Buckfire & Buckfire, P.C. Accident Attorneys Announce New Ugly Christmas Sweater Social Media Contest
7. Interlinked and InterlinkedTV Announce Heart Test Laboratories Exclusive Interview From NEAA
8. Renew Announces Online Treatment Finder, an Unbiased Rehab Center Guide
9. Bioforce AG Announces Doctors Comments Showing Efficacy of Echinaforce for Immune Support Now On You Tube
10. Andrew Hawley of Vintage Rock Posters Announces Finding a Vintage 1969 Jimi Hendrix 1969 Jahrhunderthalle Frankfurt Concert Poster
11. SpiritDetox.com Announces Addition of Herbal Clay Teas to Detox Product Lineup
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone ... executive with extensive sequencing and genomics experience, as Vice President of North American Capital ... will be responsible for leading the sales team in the commercialization of the HTG ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
Breaking Medicine Technology: